Additional file 1: of Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy SvedsaterHenrik StynesGillian WexJaro FrithLucy LeatherDavid CastelnuovoEmanuela DetryMichelle BerryScott 2016 e-table 1: Characteristics of the studies and treatment arms included in the MTC. e-table 2: Results of mixed treatment comparisons for ICS/LABA treatments of interest (full covariate model, if available). e-table 3: Summary of findings of covariate analysis, by outcome of interest (primary analysis population; full covariate model, if available). e-table 4: Results of mixed treatment comparisons by ICS/LABA treatment. e-table 5: Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*, sensitivity analysis. e-table 6: Outcomes of assessment of alternative modelling approaches. Supplementary figure 1: Networks of study treatments, by outcome of interest (sensitivity analysis population). (PDF 705 kb)